Get started
Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PHAT chart


Full chart

PHAT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.15 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.69 USD
Net income (FY)
‪−201.59 M‬ USD
Revenue (FY)
‪682.00 K‬ USD
Shares float
‪37.51 M‬
Beta (1Y)
0.43

Employees


Employees (FY)
452
Change (1Y)
+340 +303.57%
Revenue / Employee (1Y)
‪1.51 K‬ USD
Net income / Employee (1Y)
‪−446.00 K‬ USD

About Phathom Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Terrie Curran
Headquarters
Florham Park
Website
phathompharma.com
Founded
2018
FIGI
BBG00P5B2S19
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PHAT news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PHAT is 16.86 USD — it has decreased by −8.86% in the past 24 hours. Watch Phathom Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Phathom Pharmaceuticals, Inc. stocks are traded under the ticker PHAT.
PHAT stock has fallen by −3.05% compared to the previous week, the month change is a 2.12% rise, over the last year Phathom Pharmaceuticals, Inc. has showed a 101.19% increase.
We've gathered analysts' opinions on Phathom Pharmaceuticals, Inc. future price: according to them, PHAT price has a max estimate of 28.00 USD and a min estimate of 18.00 USD. Watch PHAT chart and read a more detailed Phathom Pharmaceuticals, Inc. stock forecast: see what analysts think of Phathom Pharmaceuticals, Inc. and suggest that you do with its stocks.
PHAT reached its all-time high on Jun 8, 2020 with the price of 64.54 USD, and its all-time low was 5.84 USD and was reached on Mar 24, 2023. View more price dynamics on PHAT chart.
See other stocks reaching their highest and lowest prices.
PHAT stock is 13.43% volatile and has beta coefficient of 0.43. Track Phathom Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Phathom Pharmaceuticals, Inc. there?
Today Phathom Pharmaceuticals, Inc. has the market capitalization of ‪1.15 B‬, it has increased by 7.46% over the last week.
Yes, you can track Phathom Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Phathom Pharmaceuticals, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
PHAT earnings for the last quarter are −1.32 USD per share, whereas the estimation was −1.47 USD resulting in a 10.12% surprise. The estimated earnings for the next quarter are −1.20 USD per share. See more details about Phathom Pharmaceuticals, Inc. earnings.
Phathom Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪16.35 M‬ USD, despite the estimated figure of ‪12.61 M‬ USD. In the next quarter, revenue is expected to reach ‪25.16 M‬ USD.
PHAT net income for the last quarter is ‪−85.58 M‬ USD, while the quarter before that showed ‪−91.45 M‬ USD of net income which accounts for 6.42% change. Track more Phathom Pharmaceuticals, Inc. financial stats to get the full picture.
No, PHAT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 452.00 employees. See our rating of the largest employees — is Phathom Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Phathom Pharmaceuticals, Inc. EBITDA is ‪−287.14 M‬ USD, and current EBITDA margin is ‪−24.45 K‬%. See more stats in Phathom Pharmaceuticals, Inc. financial statements.
Like other stocks, PHAT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Phathom Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Phathom Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Phathom Pharmaceuticals, Inc. stock shows the buy signal. See more of Phathom Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.